great hills semaglutide GLP-1 Drugs from the Gray

doi:10.1002/9781119188421.ch2

SURMOUNT-5 head-to-head trial data 20.2% vs 13.7% weight loss at 72 weeks Insurance coverage comparison Oral Wegovy option (FDA approved Jan 2026) Wegovy vs Ozempic Same Drug Both contain semaglutideunderstand the dosing and coverage differences

Its a triple-agonist peptide , meaning it activates three major systems simultaneously: GLP-1 reduces hunger and slows digestion GIP enhances metabolic efficiency Glucagon increases energy expenditure This combination leads to: Eating less without constant willpower Better blood sugar regulation Increased calorie burn at rest The clinical data is already strong Even in earlier trials, the results were hard to ignore: Up to ~24% total body weight loss in Phase 2 studies Around 17% weight loss in type 2 diabetes patients , alongside improved glucose control Up to 82% reduction in liver fat in individuals with fatty liver disease This isnt just weight lossits full metabolic change

Employer-sponsored plans add another layer of complexity

SE=standard error * Statistically significant versus placebo based on the pre-specified method for controlling Type I error across multiple doses Study 2 adjusted for baseline bodyweight and diabetic status Among the 388 subjects with type 2 diabetes mellitus treated in Study 2, reductions in HbA1c from baseline (6.8%) were 0.1% for placebo compared to 0.4% and 0.4% with phentermine and topiramate extended-release 7.5 mg/46 mg and phentermine and topiramate extended-release 15 mg/92 mg, respectively

Appetite Suppression: A consequence of MC4R activation